Gallery
Photos from events, contest for the best costume, videos from master classes.
 |  |
 |  |
 |  |
 |  |
 |  |
 |  |
Choosing Gabapentin for Alzheimer Treatment. When it comes to treating Alzheimer’s disease, choosing the right medication is crucial. Gabapentin is a medication that has shown promising results in the treatment of Alzheimer’s. Gabapentin works by binding to certain receptors in the brain, which helps regulate neurotransmitter activity. Especially in older adults, gabapentin is prescribed to treat behavioral and psychological symptoms of dementia (BPSD) (Kim et al., 2008). Several studies have reported that gabapentin has a deleterious effect on cognition (Leach et al., 1997; Meador et al., 1999; Shem et al., 2018). Gabapentin has been administered to several geriatric patients with bipolar disorder and patients with dementia. It has also been reported to be successful in the treatment of a 13-year-old boy with behavioural dyscontrol, a finding that suggested a possible role for gabapentin in the treatment of other behavioural disorders. Gabapentin use was significantly associated with decline in cognitive and functional status among older adults with initially normal cognition. Further studies are needed to examine the association. We would like to show you a description here but the site won’t allow us. The results of this study in patients with probable Alzheimer's disease with behavioural alterations and serious comorbidities indicate that gabapentin provides significant and sustained efficacy in terms of behaviour, with associated reductions in caregiver burden. The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Methods: We conducted a retrospective cohort study using the National Alzheimer's Coordinating Center Uniform Data Set (UDS; September 2005-March 2021 data freeze). From the eligible sample (≥age 65 years), we identified cognitively normal new-users of gabapentin and the visit they initiated gabapentin (i.e., index visit). Conclusion: Patients treated with gabapentin or pregabalin had an increased risk of dementia. Therefore, these drugs should be used with caution, particularly in susceptible individuals. Keywords: dementia, Alzheimer disease, cognitive impairment, gabapentin (GBP), pregabalin (PGB) Several case reports describe using gabapentin, an anti-epileptic and FDA-approved treatment for neuropathic pain, as an off-label treatment for BPSD. BPSD in some patients may be driven by unreported neuropathic pain, which gabapentin can treat effectively. Additionally, gabapentin has known anxiolytic properties that can theoretically improve The gabapentin treatment with a daily dose of 200–3600 mg decreased agitation and improved cognition. The result was based on low-grade evidence [ 242 ]. A double-blind phase IV RCT of gabapentin enacarbil is continuing to investigate the therapeutic efficacy of nighttime agitation and restless leg syndrome in patients with moderate to severe While most reports were in Alzheimer's, vascular or mixed Alzheimer's/vascular dementia, there were a small number with other diagnoses, including two who had frontotemporal dementia (one pure FTD and one FTD in combination with Alzheimer's). Drug treatments for BPSD in FTD have been studied much less extensively with only the antidepressant Next, it is unclear whether gabapentin is equally efficacious in Alzheimer’s dementia versus concomitant Alzheimer’s and vascular dementia. Additionally, the age difference of 17?years may have also contributed to the 97-year old’s limited response to gabapentin. Also, the first patient received a total gabapentin dose of 300mg The WHO estimates that by 2050, the global count of those with dementia will grow from 55 million in 2019 to nearly 139 million (World Alzheimer Report 2022 Life After Diagnosis: Navigating Treatment, Care and Support, 2022). GABA is the primary inhibitory neurotransmitter in the central nervous system and GABAergic neurons provide extensive innervation to cholinergic and glutamatergic neurons. It has been shown that dysfunction of the GABAergic system may contribute to cognitive impairment in humans. Gabapentin has been increasingly prescribed to older adults for off-label indications, and accumulating evidence suggests potential for gabapentin misuse and related adverse events. However, the relation between gabapentin initiation and longer-term neurocognitive changes is not well understood. Our patient, a 77-year-old Czech woman with incipient vascular dementia, received gabapentin 400mg at bedtime for 6 months and showed convincing improvement. Gabapentin was very effective in treating nocturnal agitation. Keywords: gabapentin, sleep, nocturnal agitation. The authors describe the use of gabapentin in the treatment of 4 outpatients with dementia-associated agitation. On the basis of clinical case reports and the Overt Agitation Severity Scale, all 4 patients had reduced agitation with gabapentin. Three of 4 patients were successfully titrated to a full dose of 2,400mg/day. These findings suggest a possible role for gabapentin in the behavioral Complementing this formal systematic review, an illustrative case of a patient with BPSD in mixed Alzheimer's/vascular dementia, who appeared to derive benefits in terms of symptom control and functioning from the introduction of gabapentin titrated up to 3600 mg day-1 alongside other interventions, is presented. Aim: To evaluate low dose gabapentin in treatment of disruptive behavioral symptoms in patients with moderate- severe dementia with Lewy bodies. Findings: Improvement in symptoms seen by clinician and caregivers supported by changes on respective scales.
Articles and news, personal stories, interviews with experts.
Photos from events, contest for the best costume, videos from master classes.
| |
| |
| |
| |
| |
| |